These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 24114861)

  • 1. Traditional multiplicity adjustment methods in clinical trials.
    Dmitrienko A; D'Agostino R
    Stat Med; 2013 Dec; 32(29):5172-218. PubMed ID: 24114861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Key multiplicity issues in clinical drug development.
    Dmitrienko A; D'Agostino RB; Huque MF
    Stat Med; 2013 Mar; 32(7):1079-111. PubMed ID: 23044723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advanced multiplicity adjustment methods in clinical trials.
    Alosh M; Bretz F; Huque M
    Stat Med; 2014 Feb; 33(4):693-713. PubMed ID: 24105821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Superchain procedures in clinical trials with multiple objectives.
    Kordzakhia G; Dmitrienko A
    Stat Med; 2013 Feb; 32(3):486-508. PubMed ID: 22903837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An introduction to multiplicity issues in clinical trials: the what, why, when and how.
    Li G; Taljaard M; Van den Heuvel ER; Levine MA; Cook DJ; Wells GA; Devereaux PJ; Thabane L
    Int J Epidemiol; 2017 Apr; 46(2):746-755. PubMed ID: 28025257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Penalty-based approaches to evaluating multiplicity adjustments in clinical trials: Traditional multiplicity problems.
    Paux G; Dmitrienko A
    J Biopharm Stat; 2018; 28(1):146-168. PubMed ID: 29172961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gatekeeping procedures with clinical trial applications.
    Dmitrienko A; Tamhane AC
    Pharm Stat; 2007; 6(3):171-80. PubMed ID: 17583553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overview of multiple testing methodology and recent development in clinical trials.
    Wang D; Li Y; Wang X; Liu X; Fu B; Lin Y; Larsen L; Offen W
    Contemp Clin Trials; 2015 Nov; 45(Pt A):13-20. PubMed ID: 26210511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Penalty-based approaches to evaluating multiplicity adjustments in clinical trials: Advanced multiplicity problems.
    Paux G; Dmitrienko A
    J Biopharm Stat; 2018; 28(1):169-188. PubMed ID: 29125802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sample size calculations with multiplicity adjustment for longitudinal clinical trials with missing data.
    Lu K
    Stat Med; 2012 Jan; 31(1):19-28. PubMed ID: 22162151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Issues of simultaneous tests for noninferiority and superiority.
    Ng TH
    J Biopharm Stat; 2003 Nov; 13(4):629-39; discussion 641-62. PubMed ID: 14584713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiplicity and flexibility in clinical trials.
    Brannath W; Koenig F; Bauer P
    Pharm Stat; 2007; 6(3):205-16. PubMed ID: 17674349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Test for the consistency of noninferiority from multiple clinical trials.
    Yan X; Wang MC; Su X
    J Biopharm Stat; 2007; 17(2):265-78. PubMed ID: 17365223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiplicity-adjusted sample size requirements: a strategy to maintain statistical power with Bonferroni adjustments.
    Leon AC
    J Clin Psychiatry; 2004 Nov; 65(11):1511-4. PubMed ID: 15554764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statistical planning to address strongly correlated endpoints for inferential subgroups: An innovative approach for an illustrative clinical trial with complex multiplicity issues.
    Sun H; Binkowitz B; Koch GG
    J Biopharm Stat; 2017; 27(3):399-415. PubMed ID: 28267412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mixture-based gatekeeping procedures for multiplicity problems with multiple sequences of hypotheses.
    Dmitrienko A; Kordzakhia G; Brechenmacher T
    J Biopharm Stat; 2016; 26(4):758-80. PubMed ID: 26247744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How to deal with multiple treatment or dose groups in randomized clinical trials?
    Hothorn LA
    Fundam Clin Pharmacol; 2007 Apr; 21(2):137-54. PubMed ID: 17391286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Power and sample size when multiple endpoints are considered.
    Senn S; Bretz F
    Pharm Stat; 2007; 6(3):161-70. PubMed ID: 17674404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multistage and mixture parallel gatekeeping procedures in clinical trials.
    Dmitrienko A; Kordzakhia G; Tamhane AC
    J Biopharm Stat; 2011 Jul; 21(4):726-47. PubMed ID: 21516566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of gatekeeping strategies in confirmatory clinical trials.
    Dmitrienko A; Millen BA; Brechenmacher T; Paux G
    Biom J; 2011 Nov; 53(6):875-93. PubMed ID: 22069199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.